Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 27

Results For "Varian"

325 News Found

Govt reviews public health preparedness with states/UTs over Omicron
Policy | November 30, 2021

Govt reviews public health preparedness with states/UTs over Omicron

The Omicron variant doesn't escape RTPCR and RAT; States advised to ramp up testing for prompt and early identification of any cases


Covishield effectiveness during the second wave at 63 per cent
Public Health | November 30, 2021

Covishield effectiveness during the second wave at 63 per cent

Vaccine effectiveness of complete vaccination against the moderate-to-severe disease was at 81 per cent


UAE authorises Sputnik Light vaccine as universal booster
News | November 30, 2021

UAE authorises Sputnik Light vaccine as universal booster

Booster dose is available to all residents aged 18+ and can be applied six months after the second dose of any other vaccine administered in UAE


Thermo Fisher Scientific confirms its TaqParth Covid-19 kit can detect Omicron
Medical Device | November 29, 2021

Thermo Fisher Scientific confirms its TaqParth Covid-19 kit can detect Omicron

The Omicron variant, which was designated a variant of concern by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone


Bharat Biotech updates on the Lancet study on Covaxin efficacy
News | November 25, 2021

Bharat Biotech updates on the Lancet study on Covaxin efficacy

An effectiveness result of 50 per cent achieved during the peak delta variant Covid-19 wave in India, in a highrisk study population of physicians and healthcare workers, in a hospital environment, provides insights into the efficacy and effectiveness of Covaxin


Sputnik Light in India by December: RDIF
News | November 25, 2021

Sputnik Light in India by December: RDIF

One-shot Sputnik Light is a highly effective vaccine when used both on standalone basis and applied as a booster


Arrowhead Pharmaceuticals enters agreement with GSK to develop NASH drug candidate
Biotech | November 24, 2021

Arrowhead Pharmaceuticals enters agreement with GSK to develop NASH drug candidate

Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales


Merck showcases potential for several cancers, MS and lupus
News | November 22, 2021

Merck showcases potential for several cancers, MS and lupus

Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline


Oravax and Genomma JV to commercialise Covid-19 vaccine in Mexico and Latam
Biotech | November 20, 2021

Oravax and Genomma JV to commercialise Covid-19 vaccine in Mexico and Latam

Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical


European Commission approves Ronapreve to treat Covid-19
Drug Approval | November 13, 2021

European Commission approves Ronapreve to treat Covid-19

Data demonstrates Ronapreve reduced risk of hospitalisation in certain patients and reduced risk of symptomatic Covid-19 infections in people exposed to the virus